These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 24774741)

  • 1. Does CHA₂DS₂-VASc score select patients who will benefit most from anticoagulation?
    Pueo E; Campos B; Anguita M; Worner F
    Rev Esp Cardiol (Engl Ed); 2014 May; 67(5):417-8. PubMed ID: 24774741
    [No Abstract]   [Full Text] [Related]  

  • 2. Does CHA₂DS₂-VASc score select patients who will benefit most from anticoagulation? Response.
    Barrios V; Escobar C
    Rev Esp Cardiol (Engl Ed); 2014 May; 67(5):418. PubMed ID: 24774742
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of antithrombotic therapy according to CHA2DS2-VASc score in patients with atrial fibrillation in primary care.
    Barrios V; Escobar C; Calderón A; Rodríguez Roca GC; Llisterri JL; Polo García J
    Rev Esp Cardiol (Engl Ed); 2014 Feb; 67(2):150-1. PubMed ID: 24795129
    [No Abstract]   [Full Text] [Related]  

  • 4. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
    Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB
    J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valvular-CHADS-VASc as a safer alternative to CHADS-VASc score.
    Chatzimavridou-Grigoriadou V; Kanavidis P; Mathioudakis AG
    Int J Cardiol; 2016 Oct; 221():1051-2. PubMed ID: 27447814
    [No Abstract]   [Full Text] [Related]  

  • 6. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy.
    Coppens M; Eikelboom JW; Hart RG; Yusuf S; Lip GY; Dorian P; Shestakovska O; Connolly SJ
    Eur Heart J; 2013 Jan; 34(3):170-6. PubMed ID: 23018151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Atrial fibrillation and stroke].
    Aamodt AH; Sandset PM; Atar D; Tveit A; Russell D
    Tidsskr Nor Laegeforen; 2013 Aug; 133(14):1453-7. PubMed ID: 23929293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
    Albert NM
    Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Stroke prevention in atrial fibrillation.
    Voukalis C; Shantsila E; Lip GY
    J R Coll Physicians Edinb; 2017 Mar; 47(1):13-23. PubMed ID: 28569277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of antithrombotic therapy in patients with atrial fibrillation in primary care. Importance of INR control.
    Leal-Hernández M; Marín F
    Rev Esp Cardiol (Engl Ed); 2014 May; 67(5):419. PubMed ID: 24774743
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of antithrombotic therapy in patients with atrial fibrillation in primary care. Importance of INR control. Response.
    Escobar C; Barrios V
    Rev Esp Cardiol (Engl Ed); 2014 May; 67(5):420. PubMed ID: 24774744
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of Antiplatelet Therapy in Stroke Prevention in Patients With Atrial Fibrillation.
    Manaktala R; Kluger J
    J Am Osteopath Assoc; 2017 Dec; 117(12):761-771. PubMed ID: 29181519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort.
    Lip GY; Frison L; Halperin JL; Lane DA
    Stroke; 2010 Dec; 41(12):2731-8. PubMed ID: 20966417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial Fibrillation.
    Golive A; May HT; Bair TL; Jacobs V; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2017 Jul; 120(1):75-82. PubMed ID: 28483209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
    Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP
    Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The importance of oral anticoagulation in patients with atrial fibrillation for stroke prevention].
    Neundörfer B
    Fortschr Neurol Psychiatr; 2008 Jul; 76(7):383-4. PubMed ID: 18604771
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort.
    Shantsila E; Wolff A; Lip GY; Lane DA
    Br J Gen Pract; 2015 Jan; 65(630):e16-23. PubMed ID: 25548312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice.
    Lip GY
    Thromb Haemost; 2010 Apr; 103(4):683-5. PubMed ID: 20135056
    [No Abstract]   [Full Text] [Related]  

  • 19. [Appropriate administration of anticoagulants and antiplatelets].
    Wakisaka K; Yasaka M
    Nihon Rinsho; 2014 Jul; 72(7):1258-63. PubMed ID: 25163318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term anticoagulation or antiplatelet treatment. Only warfarin has been shown to reduce stroke risk in patients with atrial fibrillation.
    Cleland JG; Kaye GC
    BMJ; 2001 Jul; 323(7306):233; author reply 235-6. PubMed ID: 11496885
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.